BOLT - CIK 0001641281
The table below shows Bolt Biotherapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$39.85M | -$61.29M | -$69.53M | -$76.50M | -$57.07M | -$47.31M |
| Capital expenditure | $72.00K | $41.00K | $206.00K | $1.95M | $2.34M | $3.26M |
| Investing cash flow | $44.30M | $57.58M | $71.04M | $57.86M | -$232.20M | -$20.59M |
| Dividends paid | - | - | - | - | - |
Bolt Biotherapeutics, Inc. reported operating cash flow of -$39.85M for fiscal year 2025. That is up 35.0% from -$61.29M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$47.31M (FY 2020) to -$39.85M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $19.00K | $108.00K | $253.00K | $503.00K | $311.11M | $39.60M |